Merck, known as MSD outside of the United States and Canada, and Eisai announced results from the phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients ...

Good morning, and welcome to today's Amneal Pharmaceuticals Investor Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DiMeo. Good morning, and thank you for joining ...

Now, it’s worth noting Stock Advisor’s total average return is 986 % — a market-crushing outperformance compared to 199% for ...

TuHURA Biosciences, Inc. ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has ...

10x Science has raised a $4.8 million seed round to help pharmaceutical researchers understand complex molecules.

Inhibrx Biosciences has drawn interest from drugmakers including Merck & Co , Germany’s Merck KGaA and Japan's Ono ...

Researchers are gaining a new appreciation for the genes on the X and Y chromosomes and how they shape sex differences in ...

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.